Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630247 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT06630247 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 9 participants.
The verdict
NCT06630247, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.
Interventions
- DRUG XL495
- DRUG ADC cytotoxic agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06630247
The ClinicalTrials.gov registry entry for NCT06630247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XL495 is the first listed.
NCT06630247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06630247 about?
NCT06630247 is a clinical study titled "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors". The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or availabl...
What is the current status of trial NCT06630247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2024-10-17. Estimated completion is 2025-05-07.
What interventions are being tested in trial NCT06630247?
The interventions under investigation include: XL495 (DRUG), ADC cytotoxic agents (DRUG).
Who is sponsoring clinical trial NCT06630247?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.